| dc.contributor |
Médecins Sans Frontières, Geneva, Switzerland. yolanda.muller@geneva.msf.org |
|
| dc.creator |
Mueller, Y |
|
| dc.creator |
Mbulamberi, Dawson B |
|
| dc.creator |
Odermatt, Peter |
|
| dc.creator |
Hoffmann, Axel |
|
| dc.creator |
Loutan, Louis |
|
| dc.creator |
Chappuis, François |
|
| dc.date |
2009-08 |
|
| dc.date.accessioned |
2017-01-31T07:16:15Z |
|
| dc.date.available |
2017-01-31T07:16:15Z |
|
| dc.identifier |
Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. 2009, 14 (8):910-7 Trop. Med. Int. Health |
|
| dc.identifier |
1365-3156 |
|
| dc.identifier |
19552645 |
|
| dc.identifier |
10.1111/j.1365-3156.2009.02305.x |
|
| dc.identifier |
http://hdl.handle.net/10144/91286 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/91286 |
|
| dc.identifier |
Tropical Medicine & International Health : TM & IH |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/91286 |
|
| dc.description |
OBJECTIVE: To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda. METHODS: Retrospective analysis of VL patients' clinical data collected for project monitoring by Médecins Sans Frontières in Amudat, eastern Uganda. RESULTS: Between 2000 and 2005, of 3483 clinically suspect patients, 53% were confirmed with primary VL. Sixty-two per cent were children <16 years of age with a male/female ratio of 2.2. The overall case-fatality rate during pentavalent antimonial (n = 1641) or conventional amphotericin B treatment (n = 217) was 3.7%. There was no difference in the case-fatality rate between treatment groups (P > 0.20). The main risk factors for in-hospital death identified by a multivariate analysis were age <6 years and >15 years, concomitant tuberculosis or hepatopathy, and drug-related adverse events. The case-fatality rate among patients >45 years of age was strikingly high (29.0%). CONCLUSION: Subgroups of VL patients at higher risk of death during treatment with drugs currently available in Uganda were identified. Less toxic drugs should be evaluated and used in these patients. |
|
| dc.language |
en |
|
| dc.rights |
Archived on this site with the kind permission of Wiley-Blackwell, [url]http://www.blackwell-synergy.com/loi/tmi[/url] |
|
| dc.title |
Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. |
|